NanoString Technologies

NanoString Technologies, Inc. engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June, 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

NanoString Technologies reports robust Q4 revenue and optimistic 2023 outlook

NanoString Technologies showcased strong Q4 2022 performance with revenue exceeding guidance and a positive outlook for 2023.
While facing challenges such as expected EBITDA losses and nCounter revenue decline, NanoString is leveraging opportunities in spatial biology and customer synergies.
The company's strengths lie in market-leading technology, positive customer feedback on CosMx instruments, and a cash-generating nCounter business.
Overall, NanoString's strategic focus on spatial biology and operational improvements position it for continued growth and innovation.

NanoString Technologies surpasses Q1 revenue targets, CosMx shines

NanoString Technologies had a strong Q1 2023, exceeding revenue guidance and raising full-year expectations.
Positive customer feedback and competitive positioning of CosMx in the spatial imager category are key strengths.
Challenges include EBITDA loss, capacity constraints, and shifts in product demand.
Opportunities lie in achieving cash flow breakeven, product growth, and market dominance with CosMx.

NanoString Technologies reports record Q2 revenue and strategic growth plans

NanoString Technologies delivered strong Q2 results, exceeding revenue guidance and showcasing growth in spatial biology.
The company's strategic objectives for 2023 focus on market expansion and product innovation, supported by a commitment to operational efficiency.
While facing challenges such as ongoing litigation and financial discussions, NanoString remains optimistic about its growth prospects and balance sheet strengthening.

NanoString Technologies achieves record revenue, eyes growth opportunities in 2024

NanoString Technologies reported strong revenue growth and cost reduction in Q3 2023.
Focus on spatial biology market penetration and new product offerings to drive future growth.
Legal challenges in Europe and backlog delays pose challenges to be addressed.
Improved gross margins and lower expenses expected to enhance profitability by 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

10X Genomics

UPC Denies Second Preliminary Injunction Request; Prior Injunctions Against NanoString's CosMx Products in Europe Remain in Full Effect PLEASANTON, Calif. , Oct. 10, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") has declined to issue a second preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) based on European Patent 2 794 928 B1 ("the EP 928 patent," docket No 459996/2023).

10x Genomics Comments on Second UPC Preliminary Injunction Decision

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the third quarter ended September 30, 2023, as well as a reorganization designed to accelerate the Company's path to profitability. “Our teams delivered strong revenue results for the third quarter, with preliminary results exceeding consensus estimates and the high end of our.

NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023

SINGAPORE--(BUSINESS WIRE)--A*STAR's Genome Institute of Singapore (GIS), NanoString® Technologies, Inc. (NASDAQ: NSTG), and Next Level Genomics (NLG), today announced the establishment of a joint laboratory in Singapore focusing on the application of spatial biology to identify biomarkers that can predict disease progression and treatment response. The new lab, called the SpACE-Dx lab (Spatial Atlas of Clinical Evolution of Disease), will harness spatial multiomic (gene and protein expression).

A*STAR's Genome Institute of Singapore, NanoString and Next Level Genomics Establish Joint Lab to Advance Studies of Complex Diseases with Spatial Genomics

Second Injunction Issued Against CosMx PLEASANTON, Calif. , Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023).

10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on today's order from the European Unified Patent Court (UPC) granting a preliminary injunction effective immediately in 17 Member States of the European Union against NanoString's CosMx™ Spatial Molecular Imager (SMI) products for RNA detection in NanoString's ongoing patent dispute with 10x Genomics and Harvard: “We are disappoint.

NanoString Comments on Unified Patent Court Order

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced it will host its fifth annual Spatial Genomics Summit, September 19th. The two-hour virtual event will showcase advances in the rapidly expanding field of spatial biology with talks from scientific leaders harnessing the power and utility of our spatial platforms for discovery, drug development, the quest for biomarkers and comprehe.

NanoString to Host Virtual Spatial Genomics Summit September 19

SEATTLE--(BUSINESS WIRE)--NanoString launches most comprehensive spatial proteomics panel to empower life sciences researchers to profile 500+ proteins simultaneously.

NanoString Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered

According to NanoString (NSTG), SMI's unique ability to interrogate both RNA and proteins at ultra-high plex with subcellular resolution has made it a one-of-a-kind tool.

NanoString (NSTG) Grows in Translational Research With CRO Deals

SEATTLE--(BUSINESS WIRE)-- #empoweringresearch--NanoString expands CRO network for customers.

NanoString Expands Partnerships with Contract Research Organizations Making Spatial Molecular Imaging Tools Widely Available to Global BioPharma Researchers

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for discovery and translational research, today announced that Todd Garland has been appointed Chief Commercial Officer, effective August 28, 2023. Mr. Garland is a senior executive with more than 25 years of experience in healthcare and life sciences technologies that serve customers in the discovery, translational and clinical markets. Most recently Mr. Garland served as Chief Commercial Of.

NanoString Appoints Todd Garland as Chief Commercial Officer

NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.

NanoString (NSTG) Advances in Xenotransplantation With New Study

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced today that a team of globally renowned researchers utilized two NanoString platforms, the nCounter® Analysis System and GeoMx® Digital Spatial Profiler, to decode the immune response following the transplantation of genetically modified pig kidneys into humans. The groundbreaking study featured in the August issue and an accompanyin.

NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants

NanoString Technologies, Inc. (NASDAQ:NSTG ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Doug Farrell - Vice President, Investor Relations & Corporate Communications Brad Gray - President & Chief Executive Officer Tom Bailey - Chief Financial Officer Conference Call Participants John Sourbeer - UBS Tom Peterson - Baird Operator Thank you for standing by. My name is Ian, and I will be your conference operator today.

NanoString Technologies, Inc. (NSTG) Q2 2023 Earnings Call Transcript

The headline numbers for NanoString (NSTG) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, NanoString (NSTG) Q2 Earnings: A Look at Key Metrics

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString reports Q2-23' Operating Results.

NanoString Technologies Releases Operating Results for Second Quarter of 2023

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, provided comments on yesterday's order of the United States District Court for the District of Delaware in NanoString's patent litigation with 10x Genomics and President and Fellows of Harvard College. In its order, the Court granted NanoString's motion to add new counterclaims for antitrust and unfair competition violations as well as the aff.

Delaware District Court Permits NanoString's Counterclaims that 10x Genomics and Harvard Violated the Antitrust Laws

Helen of Troy

The action is hot in Helen Of Troy NASDAQ: HELE and NanoString Technologies NASDAQ: NSTG. These unrelated companies issued better-than-expected results and guidance that have their shares up double-digits in early trading.

Helen of Troy and NanoString Technologies Trade Set-ups

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the second quarter ended June 30, 2023. “We are excited to report that our teams delivered strong preliminary revenue results for the second quarter, with preliminary results exceeding consensus estimates and the upper end of our guidance ranges,” said Brad Gray, President and.

NanoString Provides Preliminary Financial and Operational Highlights for Second Quarter of 2023

Illumina

Natera

The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive measures to maintain the well-being of larger populations.

Red-Hot Quality Opportunities in Genomics

FOSTER CITY, Calif.--(BUSINESS WIRE)--Acrobat Genomics, NanoString Technologies, Inc. (NASDAQ:NSTG), and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx® Digital Spatial Profiling (DSP) technology. This collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis. NanoString's GeoMx DSP is a powerful spa.

Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics

PARIS & SEATTLE--(BUSINESS WIRE)-- #earnings--Owkin, Nanostring (NASDAQ:NSTG), and world-leading cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander-Universität Erlangen-Nürnberg, and Charité - Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology's annual meeting (booth #4037). MOSAIC is a landmark $50 million project to revolutionize cancer.

Owkin Powers a New Era in Oncology Research with MOSAIC – An Unprecedented $50 Million Spatial Atlas of Cancer Cells

Also Files New Suit Against Vizgen's MERSCOPE Products for Patent Infringement PLEASANTON, Calif. , June 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it filed new patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and Vizgen, Inc. in the European Unified Patent Court.

10x Genomics Files Two New Lawsuits Requesting Preliminary Injunctions Against NanoString's CosMx Products

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the Jefferies Healthcare Conference, which will be held June 7-9, 2023. Brad Gray, president and chief executive officer, is scheduled to present on Thursday, June 8, 2023, at 8:30am ET. Interested parties can access the live webcast from the investor section o.

NanoString to Webcast Presentation from Jefferies Healthcare Conference

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will host a conference call on Monday, May 22, 2023, at 4:30pm ET to provide an update on the recent Decision of the Regional Court of Munich. Investors and other interested parties should register for the conference call in advance by visiting https://www.netroadshow.com/events/login?show=9b96aaa1&confId=5.

NanoString to Host Conference Call on Monday, May 22, 2023, to Provide Comments on Decision of the Regional Court of Munich

NanoString Technologies may have to stop selling certain instruments and reagents in Germany. The company said it plans to appeal the ruling.

News for NanoString Technologies Stock (NSTG)